# Structure (GPCR) — News

GPCR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gpcr/news

## Recent headlines

- [Structure's ACCG-2671 cuts weight 3.3% in single dose](https://www.ainvest.com/news/structure-accg-2671-cuts-weight-3-3-single-dose-2609) — AInvest Wire, Sep 8, 2026
  Structure Therapeutics Inc. (NASDAQ: GPCR) has reported preclinical data indicating that its lead oral small molecule amylin receptor agonist, ACCG-2671, achieved a 3.3% body weight reduction following a single dose in animal models. The compound, a dual amylin and calcitonin receptor agonist…
- [Structure Therapeutics reports positive clinical data across oral small molecule amylin and GLP-1 programs for chronic weight management](https://www.ainvest.com/news/structure-therapeutics-reports-positive-clinical-data-oral-small-molecule-amylin-glp-1-programs-chronic-weight-management-2609) — AInvest Wire, Sep 8, 2026
  Structure Therapeutics Inc. (NASDAQ: GPCR) has reported positive clinical data across its oral small molecule amylin and GLP-1 programs for chronic weight management, highlighting progress in its development pipeline for metabolic diseases. The company’s lead GLP-1 candidate, aleniglipron…
- [Structure Therapeutics Inc: H.C. Wainwright cuts target price to $70 from $100](https://www.ainvest.com/news/structure-therapeutics-wainwright-cuts-target-price-70-100-2606) — AInvest Wire, Jun 11, 2026
  On June 11, 2026, H.C. Wainwright revised its price target for Structure Therapeutics Inc. (NASDAQ:GPCR), lowering it to $70 from a previous $100, while maintaining a Buy rating on the shares. This adjustment reflects a reassessment of the company’s valuation in light of evolving market dynamics…
- **Important** — Structure Therapeutics plunges 45% premarket on new GLP-1 drug data — AInvest Wire, Dec 18, 2023
  Structure Therapeutics plunges 45% premarket on new GLP-1 drug data Structure Therapeutics, a small biotech company, has seen its stock prices plunge by 45% in premarket trading after new data on its GLP-1 drug was released. This new data could potentially challenge the dominance of pharmaceutical…
- Structure's obesity pill could challenge Lilly, Novo, small study suggests — AInvest Wire, Sep 29, 2023

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).